E6-associated protein is required for human papillomavirus type 16 E6 to cause cervical cancer in mice

Cancer Research

Volumn 70, Issue 12, 2010, Pages 5064-5073

  Shai, Anny ^a,b   Pitot, Henry C ^a   Lambert, Paul F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E6 ASSOCIATED PROTEIN; PROTEIN E6; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; DNA DAMAGE; EPITHELIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN PAPILLOMAVIRUS TYPE 16; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; DNA DAMAGE; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UTERINE CERVICAL NEOPLASMS;

EID: 77953747537     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-3307     Document Type: Article

References (48)

1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
2. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996;1288:F55-78.
3. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
4. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S3/11-25.
5. Sankaranarayanan R, Ferlay J. Worldwide burden of gynaecological cancer: the size of the problem. Best Pract Res Clin Obstet Gynaecol 2006;20:207-25.
6. Durst M, Kleinheinz A, Hotz M, Gissmann L. The physical state of human papillomavirus type 16 DNA in benign and malignant genital tumours. J Gen Virol 1985;66:1515-22.
7. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci U S A 1995;92:1654-8.
8. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21.
9. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989;8:3905-10.
10. Herber R, Liem A, Pitot H, Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Virol 1996;70:1873-81. (Pubitemid 26062951)
11. Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A 1996;93:2930-5.
12. Song S, Liem A, Miller JA, Lambert PF. Human papillomavirus types 16 E6 and E7 contribute differently to carcinogenesis. Virology 2000;267:141-50.
13. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
14. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991;10:4129-35.
15. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
16. Matsumoto Y, Nakagawa S, Yano T, et al. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6. J Med Virol 2006;78:501-7.
17. Kuhne C, Banks L. E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem 1998;273:34302-9.
18. Huibregtse JM, Scheffner M, Howley PM. E6-AP directs the HPV E6-dependent inactivation of p53 and is representative of a family of structurally and functionally related proteins. Cold Spring Harb Symp Quant Biol 1994;59:237-45.
19. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505. (Pubitemid 23335075)
20. Shai A, Nguyen ML, Wagstaff J, Jiang YH, Lambert PF. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP. Oncogene 2007;26:3321-8.
21. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP. Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 2007;26:4059-70.
22. Massimi P, Shai A, Lambert P, Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 2008;27:1800-4.
23. Riley RR, Duensing S, Brake T, Munger K, Lambert PF, Arbeit JM. Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res 2003;63:4862-71.
24. Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res 2007;67:1626-35.
25. Shai A, Pitot HC, Lambert PF. p53 loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008;68:2622-31.
26. Simonson SJ, Difilippantonio MJ, Lambert PF. Two distinct activities contribute to human papillomavirus 16 E6's oncogenic potential. Cancer Res 2005;65:8266-73.
27. Nawaz Z, Lonard DM, Smith CL, et al. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999;19:1182-9.
28. Sivaraman L, Nawaz Z, Medina D, Conneely OM, O'Malley BW. The dual function steroid receptor coactivator/ubiquitin protein-ligase integrator E6-AP is overexpressed in mouse mammary tumorigenesis. Breast Cancer Res Treat 2000;62:185-95.
29. Gao X, Mohsin SK, Gatalica Z, Fu G, Sharma P, Nawaz Z. Decreased expression of E6-associated protein in breast and prostate carcinomas. Endocrinology 2005;146:1707-12.
30. Chung SH, Wiedmeyer K, Shai A,Korach KS, Lambert PF. Requirement for estrogen receptor α in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res 2008;68:9928-34.
31. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A 1998;95:2290-5.
32. Jiang YH, Armstrong D, Albrecht U, et al. Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. Neuron 1998;21:799-811. (Pubitemid 28498788)
33. Li L, Li Z, Howley PM, Sacks DB. E6AP and calmodulin reciprocally regulate estrogen receptor stability. J Biol Chem 2006;281:1978-85.
34. Hewitt SC, Deroo BJ, Hansen K, et al. Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Mol Endocrinol 2003;17:2070-83.
35. Ferreira M, Crespo M, Martins L, Felix A. HPV DNA detection and genotyping in 21 cases of primary invasive squamous cell carcinoma of the vagina. Mod Pathol 2008;21:968-72.
36. Koyamatsu Y, Yokoyama M, Nakao Y, et al. A comparative analysis of human papillomavirus types 16 and 18 and expression of p53 gene and Ki-67 in cervical, vaginal, and vulvar carcinomas. Gynecol Oncol 2003;90:547-51.
37. Brake T, Connor JP, Petereit DG, Lambert PF. Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model: identification of minichromosome maintenance protein 7 as an informative biomarker for human cervical cancer. Cancer Res 2003;63:8173-80.
38. Balsitis S, Dick F, Dyson N, Lambert PF. Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res 2006;66:9393-400.
39. Malanchi I, Accardi R, Diehl F, et al. Human papillomavirus type 16 E6 promotes retinoblastoma protein phosphorylation and cell cycle progression. J Virol 2004;78:13769-78.
40. Seavey SE, Holubar M, Saucedo LJ, Perry ME. The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). J Virol 1999;73:7590-8.
41. Eichten A, Westfall M, Pietenpol JA, Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16 E7 oncoprotein. Virology 2002;295:74-85.
42. Bilder D, Perrimon N. Localization of apical epithelial determinants by the basolateral PDZ protein Scribble. Nature 2000;403:676-80.
43. Bilder D, Li M, Perrimon N. Cooperative regulation of cell polarity and growth by Drosophila tumor suppressors. Science 2000;289:113-6.
44. Humbert P, Russell S, Richardson H. Dlg, Scribble and Lgl in cell polarity, cell proliferation and cancer. Bioessays 2003;25:542-53.
45. Lin HT, Steller MA, Aish L, Hanada T, Chishti AH. Differential expression of human Dlg in cervical intraepithelial neoplasias. Gynecol Oncol 2004;93:422-8.
46. Nakagawa S, Yano T, Nakagawa K, et al. Analysis of the expression and localisation of a LAP protein, human scribble, in the normal and neoplastic epithelium of uterine cervix. Br J Cancer 2004;90:194-9.
47. Thomas MC, Chiang CM. E6 oncoprotein represses p53-dependent gene activation via inhibition of protein acetylation independently of inducing p53 degradation. Mol Cell 2005;17:251-64.
48. Zimmermann H, Koh CH, Degenkolbe R, et al. Interaction with CBP/p300 enables the bovine papillomavirus type 1 E6 oncoprotein to downregulate CBP/p300-mediated transactivation by p53. J Gen Virol 2000;81 Pt 11:2617-23.